CAR T-cell Therapy: A Deeper Dive into Adverse Effects and Financial Toxicities

Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center and Gunjan Shah, MD, Memorial Sloan Kettering Cancer Center Recorded live at The Leukemia & Lymphoma Society’s Symposium on CAR T-cell Therapy on June 28, 2019 Tune in as Dr. Sergio Giralt and Dr. Gunjan Shah, hematologist-oncologists at Memorial Sloan Kettering Cancer Center in New York, discuss adverse effects and financial toxicities associated with chimeric antigen receptor (CAR) T-cell therapy. In this episode, Dr. Giralt discusses how cytokine release syndrome (CRS), neurotoxicities, and other side effects affect patients receiving CART therapy, and Dr. Shah reviews the challenges associated with the high cost of treatment and care. Sergio Giralt, MD Chief Attending Adult Bone Marrow Transplant Service Memorial Sloan Kettering Cancer Center New York, NY Gunjan Shah, MD Adult Bone Marrow Transplant Servicefor Health Policy & OutcomesMemorial Sloan Kettering Cancer Center New York, NY